This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Sector Weekly Rewind

Stocks in this article: AMLN ALKS GILD ALXN TSPT SOMX GENZ

BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that was Oct. 18, 2010:

The weekly shocker: U.S. regulators reject Amylin Pharmaceuticals' (AMLN) diabetes drug Bydureon.

Not everyone was surprised by the Bydureon decision. Meet the short-seller who got Amylin right.

Amylin's Really Bad Day: Reader Mailbag.

The week's best-performing stocks in the sector: Clarient (CLRT) (39%), Verenium (VRNM) (21%), Pharmathene (PIP) (21%), Aryx Therapeutics (ARYX) (20%), Labopharm (DDS) (15%).

Alexza Pharmaceuticals (ALXA) and Valeant Pharmaceuticals (VRX) part ways over the delayed AZ-004.

Generex Biotechnology (GNBT.PK) exiled to the pink sheets.

Gilead Sciences (GILD) earns 90 cents a share (adjusted) in the third quarter on total revenue of $1.94 billion, topping Street consensus.

Genzyme (GENZ) forecasts 2011 earnings (adjusted) of $4.30-$4.60 a share, well above Street consensus of $3.85, and says Sanofi-Aventis (SNY) is significantly undervaluing the company with its $69-a-share takeover offer. Based on the valuation multiple Sanofi is using today, Genzyme is worth $89 a share, Genzyme said.

Cell Therapeutics (CTIC) issues press release about European regulatory sign-off on a plan to study pixantrone in children, then the company sells preferred shares convertible into 56.8 million common shares and warrants to raise $21 million.

This week's Biotech Stock Mailbag: Titan Pharma (TTNP.OB), Mela Sciences (MELA), AVI Biopharma (AVII), Vanda Pharmaeuticals (VNDA) and Savient Pharmaceuticals (SVNT).

Transcept Pharmaceuticals (TSPT) releases results from a highway driving study of its Intermezzo sleeping pill, plans to resubmit the drug to the FDA in the first quarter 2011.

The week's worst-performing stocks: Amylin Pharmaceuticals (AMLN) (-46%), Alkermes (ALKS) (-25%), Molecular Insight Pharmaceuticals (MIPI) (-22%), Somaxon Pharmaceuticals (SOMX) (-14%), Senesco Technologies (SNT) (-13%).

Cubist Pharmaceuticals (TSPT) sells $400 million in convertible debt.

A paragraph IV generic challenge was filed against Silenor, the sleeping pill recently launched by Somaxon Pharmaceuticals (SOMX).

Alexion Pharmaceutials (ALXN) announces positive, interim results from a pivotal study of Soliris in patients with atypical Hemolytic Uremic Syndrome. The company also reports third-quarter earnings of 50 cents a share on revenue of $141.6 million, topping Street consensus.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs